[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571261":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":27,"studyPopulation":16,"armGroups":28,"interventions":41,"overallOfficials":16,"centralContacts":16,"locations":16,"responsibleParty":49,"collaborators":16,"id":53,"slug":16,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":16,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":16,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":16,"overallStatus":70,"whyStopped":16,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":16},{"fullName":5,"class":6},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"ratio of successful sedation during the whole surgery","Sedation success is defined as BIS locating in the range of 40-60 according to the required dosage without additional rescue sedative during the surgical procedures.","Intraoperative period",[14],{"measure":15,"description":16,"timeFrame":12},"time interval for BIS from baseline before induction to 60",null,{"allocation":18,"interventionModel":19,"interventionModelDescription":16,"primaryPurpose":20,"observationalModel":16,"timePerspective":16,"maskingInfo":21},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":22,"maskingDescription":16,"whoMasked":23},"TRIPLE",[24,25,26],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR","Remimazolam besylate (RB), as a new benzodiazepine sedative agent, has been approved in clinical anesthesia with prominent characteristics of short onset\u002Foffset, less depression for cardiovascular or respiratory function and specific antagonist. Some studies have confirmed the comparable anesthesia efficacy of remimazolam for outpatient digestive endoscopy, fiberoptic bronchoscopy, facial plastic and orthopedic surgery as propofol. Currently, the evidence on its application in cardiac anesthesia is insufficient. Our study aims to evaluate the efficacy of remimazolam besylate and propofol and provide an ideal anesthetic agent to achieve the goal of early recovery after cardiac surgery.",[29,35],{"label":30,"type":31,"description":32,"interventionNames":33},"remimazolam besylate","EXPERIMENTAL","Patients received an initial dose of remimazolam (0.3mg\u002Fkg) for induction and a continuous infusion rate of 1 mg\u002Fkg\u002Fh for anesthesia maintenance.",[34],"Drug: remimazolam besylate",{"label":36,"type":37,"description":38,"interventionNames":39},"propofol","ACTIVE_COMPARATOR","Patients received an initial dose of propofol (1.0 mg\u002Fkg) and a continuous infusion rate of 1-1.5 mg\u002Fkg\u002Fh",[40],"Drug: propofol",[42,46],{"type":43,"name":30,"description":44,"armGroupLabels":45,"otherNames":16},"DRUG","Patients received an initial dose of remimazolam (0.3mg\u002Fkg) for induction and a continuous infusion rate of 1 mg\u002Fkg\u002Fh for anesthesia maintenance. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.",[30],{"type":43,"name":36,"description":47,"armGroupLabels":48,"otherNames":16},"Patients received an initial dose of propofol (1.0 mg\u002Fkg) and a continuous infusion rate of 1-1.5 mg\u002Fkg\u002Fh. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.",[36],{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"PRINCIPAL_INVESTIGATOR","SHI Jia","director of department of Anesthesiology","100571261",false,"NCT06717945","The Efficacy and Safety of Remimazolam Besylate for Cardiac Anesthesia","Inclusion Criteria:\n\n1. Elective cardiac surgery via cardiopulmonary bypass;\n2. Aged 18-65 years;\n3. American Society of Anesthesiologists (ASA) grade I-III;\n4. Body mass index (BMI) 18-28 kg\u002Fm2.\n\nExclusion Criteria:\n\n1. A history of sternotomy for heart disease;\n2. Angina or arrhythmia with severe dynamics flutters pre-operation;\n3. Respiratory, hepatic or renal dysfunction (oxygenation index\\\u003C300, alanine transaminase\\> 2 upper limits of normal value, creatinine \\> 200 μmol\u002FL);\n4. Diagnosed with advanced tumors;\n5. Psychiatric or mental disorders;\n6. Myasthenia gravis or seizures;\n7. Pregnant or lactating females;\n8. A history of benzodiazepines administration within 3 months before surgery;\n9. Known allergic to benzodiazepines, opioids, propofol and flumazenil;\n10. Involved in another interventional clinical trial.","ALL","18 Years","65 Years",{"count":62,"type":63},320,"ESTIMATED","INTERVENTIONAL",[66],"EARLY_PHASE1","The evidence on the practice of remimazolam besylate during cardiac anesthesia is scarce. This study investigates the efficacy and safety of remimazolam besylate general induction and maintenance during cardiac surgery.",[69],"Anesthesia","NOT_YET_RECRUITING","2024-12-01",{"date":73,"type":74},"2024-12-05","ACTUAL",{"date":76,"type":63},"2025-01",{"date":78,"type":63},"2025-06",{"name":5,"class":6}]